Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
|Videos|January 6, 2021
Tobacco cessation critical to preventing bladder cancer recurrence
Author(s)Urology Times staff
Vikram M. Narayan, MD, discusses how smoking is the most significant known risk factor for bladder cancer.
Advertisement
Vikram M. Narayan, MD, of Emory University, Winship Cancer Institute, Atlanta, GA, discusses how smoking, including secondhand smoke, is often the single leading cause of bladder cancer.
Advertisement
Related to this article
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
The agency issued a PDUFA target action date of June 14, 2027.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
2
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
3
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
4
In situ immunotherapy shows encouraging survival findings in prostate cancer
5